3 March 2025 in Journal for ImmunoTherapy of Cancer
Background: No established biomarker exists for specific myeloid cell populations or in gastric cancer. This study aimed to explore the prognostic and immunological relevance of plasma translationally controlled tumor protein (TCTP) in patients with advanced gastric cancer treated with an immune checkpoint inhibitor and/or cytotoxic chemotherapy. Methods: Plasma samples were prospectively collected from the cohorts of patients with gastric cancer treated with first-line fluoropyrimidine plus platinum chemotherapy (n=143, cohort 1) and third-line nivolumab (n=165, cohort 2). Plasma TCTP levels were quantified using ELISA, and multiplex proteomic analysis (Olink) was conducted to assess expression levels of immune-related proteins. External single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics datasets were employed to validate the findings. Results: Patients with high plasma TCTP levels (TCTP-high group) exhibited poor progression-free survival (PFS) and overall survival (OS) with first-line chemotherapy compared with those with low levels (TCTP-low group) in cohort 1 (HR: 1.73 for PFS; 1.77 for OS). In the TCTP-high group, proteins associated with immunosuppressive myeloid cells, angiogenesis, and immune exclusion of T/natural killer (NK) cell function were upregulated, whereas proteins involved in T-cell activation/exhaustion were significantly upregulated in the TCTP-low group. scRNA-seq analyses identified a myeloid subset with high TPT1 (encoding TCTP) expression and TCTP-related molecules, enriched with inhibitory myeloid inflammation gene signatures and providing inhibitory signals to T/NK cells (Macrophage-chemokine). Spatial transcriptomics analyses revealed a tumor-cell-enriched cluster co-localized with the Macrophage-chemokine subset, which exhibited the highest TPT1 expression and a positive correlation between its abundance and average TPT1 levels. In nivolumab-treated patients (cohort 2), the high TCTP group was associated with poor survival outcomes (HR: 1.39 for PFS; 1.47 for OS). Conclusions: Plasma TCTP is a prognostic biomarker, reflecting clinically relevant immunosuppressive myeloid signals in patients with gastric cancer.
1 January 2026 in Journal of Breast Cancer
Lee S, et al. J Breast Cancer. 2026 ;29:e9. https://doi.org/10.4048/jbc.2025.0256
31 December 2024 in Journal of Surgical Innovation and Education
Breast cancer is the most common cancer among women in Korea. Given the increased preference for breast-conserving surgery (BCS), preoperative localization is crucial, especially for non-palpable lesions, to ensure clear resection margins. Traditional methods such as wire-guided localization have limitations, including patient discomfort and wire migration. Recently, LuminoMark, an indocyanine green–macroaggregated albumin–hyaluronic acid mixture, has emerged as a promising alternative with potential benefits over existing techniques. We present a case of a 67-year-old female with a non-palpable Breast Imaging-Reporting and Data System 5 breast lesion. Preoperative localization was performed using LuminoMark, with accurate placement verified by a Lumino-imager. The lesion was successfully excised, and the absence of residual fluorescence confirmed complete resection. LuminoMark provided effective lesion localization without skin pigmentation, reducing the risk of misdiagnosis during follow-up. The procedure demonstrated a short learning curve, similar to that of charcoal localization. However, the need for a costly near-infrared fluorescence detector and the lack of long-term follow-up data are current limitations. Despite minor drawbacks, LuminoMark offers advantages over traditional localization methods, including improved aesthetics and reduced complications. This case demonstrates its feasibility as a next-generation localization technique for BCS, emphasizing the importance of an accurate injection technique to ensure adequate dispersion and complete tumor resection. Further studies are warranted to validate its long-term efficacy.